Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bipolar Mania Clear all
Terminated Phase 4 Interventional

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
15
States / cities
Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 2Phase 3 Interventional

BHV-7000 Acute Treatment of Bipolar Mania

NCT06419582
View directory record Official record
Conditions
Bipolar Disorder
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders

NCT02357290
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Open-label Treatment with N-Acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

NCT00488618
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Cariprazine (RGH-188), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 21, 2026, 10:55 PM EDT
Recruiting Phase 2 Interventional

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

NCT07288320
View directory record Official record
Conditions
Bipolar I Disorder, Mania
Interventions
NBI-1117568, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 4 Interventional

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

NCT00294255
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 21, 2026, 10:55 PM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

NCT00805493
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
9 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 21, 2026, 10:55 PM EDT
Terminated Phase 1 Interventional

Taurine in Adolescents With Bipolar Disorder

NCT00391001
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Taurine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
13 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 21, 2026, 10:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Menstrual Effects On Mood Symptoms in Bipolar Disorder

NCT00472615
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 21, 2026, 10:55 PM EDT
Terminated Phase 2 Interventional

BHV-7000 Open-Label Extension Bipolar Mania Study

NCT06423794
View directory record Official record
Conditions
Bipolar Disorder
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 2 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 3 Interventional

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

NCT00228059
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 2 Interventional

Lithium for the Treatment of Pediatric Mania

NCT00442039
View directory record Official record
Conditions
Bipolar I Disorder Without Psychotic Symptoms
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 21, 2026, 10:55 PM EDT
Terminated Phase 4 Interventional Results available

Allopurinol Maintenance Study for Bipolar Disorder

NCT00732251
View directory record Official record
Conditions
Bipolar Disorder, Mania, Mixed Mania
Interventions
Allopurinol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 21, 2026, 10:55 PM EDT
Terminated Phase 4 Interventional

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

NCT02623504
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Orlando, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 4 Interventional

Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

NCT00050206
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder

NCT00257972
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Riverside, California • Deerfield Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020
View directory record Official record
Conditions
Bipolar Disorder
Interventions
divalproex ER, quetiapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Phase 4 Interventional

Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder

NCT00227968
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Interpersonal Social Rhythm Therapy (IPSRT), Clinical Status and Symptom Response Therapy (CSSRT)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 21, 2026, 10:55 PM EDT
Completed Not applicable Interventional

A Study of Spoken Language in Mania

NCT05956340
View directory record Official record
Conditions
Manic Episode, Bipolar I Disorder
Interventions
Research interview
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 10:55 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 21, 2026, 10:55 PM EDT